Application of time-dependent modeling for the exposure–efficacy analysis of ceritinib in untreated ALK-rearranged advanced NSCLC patients

Purpose Ceritinib 750 mg/day was approved for the treatment of patients with untreated anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) based on ASCEND-4 study. The objective of this article is to introduce the use of time-dependent modeling approach in the updated exposure–efficacy analysis of ceritinib for the first-line indication.